Lifestyle changes associated with the use of GLP-1 agonists and SGLT2 inhibitors are recommended for the treatment of T2DM in women, with beneficial effects on weight reduction and metabolic parameters, such as glycated hemoglobin reduction. Metformin should not be used as a first-line agent for the management of diabetes in pregnancy, and, when used to treat POS and induce ovulation, it should be discontinued up to the end of the first trimester, because it crosses the placental barrier. This evidence concerns the gene SLC5A2 and diabetes mellitus.